ReviewAnatolian journal of cardiology2019
Role of interleukins in heart failure with reduced ejection fraction.
Review in Anatolian journal of cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 45 citations in OpenAlex.
- Glycocalyx Disintegration Is Associated with Mortality in Chronic Heart Failure.Journal of clinical medicine · 2025Article
- Gut Microbiota in Heart Failure-The Role of Inflammation.Biomedicines · 2025Review
- Review
- Interplay ofFrontiers in cardiovascular medicine · 2025Article
- The role of immune checkpoints PD-1 and CTLA-4 in cardiovascular complications leading to heart failure.Frontiers in immunology · 2025Review
- Comprehensive Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure With Reduced Ejection Fraction: A Literature Review.Journal of clinical medicine research · 2024Review
- RNA-Seq analysis of human heart tissue reveals SARS-CoV-2 infection and inappropriate activation of the TNF-NF-κB pathway in cardiomyocytes.Scientific reports · 2024Article
- Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular and Renal Outcomes in Heart Failure Patients With Type 2 Diabetes: A Literature Review.Journal of clinical medicine research · 2024Review
- Inflammation in heart failure: pathophysiology and therapeutic strategies.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Review
- A bioinformatics approach to elucidate conserved genes and pathways in C. elegans as an animal model for cardiovascular research.Scientific reports · 2024Article
- Article
- Cardioprotection by the adiponectin receptor agonist ALY688 in a preclinical mouse model of heart failure with reduced ejection fraction (HFrEF).Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024Article
- Prognostic Value of Inflammatory Cytokines in Predicting Hospital Readmissions in Heart Failure with Preserved Ejection Fraction.Journal of inflammation research · 2024Article
- Inflammation in Heart Failure-Future Perspectives.Journal of clinical medicine · 2023Review
- Molecular targets and mechanisms ofWorld journal of diabetes · 2023Article
- Role of serum cytokines in the prediction of heart failure in patients with coronary artery disease.ESC heart failure · 2023Article
- Fat-to-heart crosstalk in health and disease.Frontiers in genetics · 2023Review
- Interleukin 4/13 signaling in cardiac regeneration and repair.American journal of physiology. Heart and circulatory physiology · 2022Review
- Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers.Frontiers in cardiovascular medicine · 2022Review
- Mechanism of Zhen Wu Decoction in the Treatment of Heart Failure Based on Network Pharmacology and Molecular Docking.Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is the leading cause of morbidity and mortality in developed countries, and it is the primary cause of mortality in the elderly worldwide. The processes of inflammatory response activation, production and release of pro-inflammatory cytokines, activation of the complement system, synthesis of autoantibodies, and overexpression of Class II major histocompatibility complex molecules contribute to the HF development and progression. High levels of circulating cytokines correlate with the severity of HF, measured with the use of New York Heart Association's classification, and prognosis of the disease. In HF, there is an imbalance between pro-inflammatory and anti-inflammatory cytokines. Concentrations of several interleukins are increased in HF, including IL-1β, IL-6, IL-8, IL-9, IL-10, IL-13, IL-17, and IL-18, whereas the levels of IL-5, IL-7, or IL-33 are down-regulated. Concentrations of inflammatory mediators are associated with cardiac function and can be HF markers and predictors of adverse outcomes or mortality. This review presents the role of interleukins, which contribute to the HF initiation and progression, the importance of their pathways in transition from myocardial injury to HF, and the role of interleukins as markers of disease severity and outcome predictors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.